Millennium Management
KYNB

Millennium Management’s Kyntra Bio KYNB Stock Holding History

Millennium Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,600
Closed -$243K – 6254
2023
Q2 		$243K Buy
+3,600
New +$1.49M ﹤0.01% 5019
2021
Q3 		– Sell
-1,552
Closed -$1.03M – 6916
2021
Q2 		$1.03M Buy
+1,552
New +$894K ﹤0.01% 4631

Other funds holding KYNB

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Millennium Management's KYNB Position: Q2 2025 in Review

Millennium Management sold out of Kyntra Bio (KYNB) in Q2 2025, closing a stake of 17,675 shares — an estimated $137K sold.

Millennium Management first reported a position in KYNB in Q4 2014 and held it in 36 quarters. The position peaked at $11.2M in Q1 2023. 30 funds tracked by Wall St. Rank hold KYNB as of Q2 2025.

  • Millennium Management reported no remaining Kyntra Bio position as of Q2 2025 after selling out during the quarter.
  • Millennium Management sold 17,675 Kyntra Bio shares in Q2 2025, an estimated $137K.
  • Millennium Management first reported a position in Kyntra Bio in Q4 2014 and held it in 36 quarters.
  • Millennium Management's Kyntra Bio position peaked at $11.2M in Q1 2023.
  • 30 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2025.

Based on Millennium Management's 13F filing for Q2 2025, filed 14 Aug 2025.